EP
URGN icon

Essential Partners’s UroGen Pharma URGN Stock Holding History

Essential Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77K Sell
48
-70
-59% -$1.9K ﹤0.01% 2027
2026
Q1 		$2.12K Hold
118
– – ﹤0.01% 1987
2025
Q4 		$2.76K Buy
118
+3
+3% +$65 ﹤0.01% 1688
2025
Q3 		$2.29K Buy
115
+7
+6% +$126 ﹤0.01% 1752
2025
Q2 		$1.48K Buy
+108
New +$1.04K ﹤0.01% 1406

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Essential Partners's URGN Position: Q2 2026 in Review

Essential Partners reduced its UroGen Pharma (URGN) stake by 59% in Q2 2026, selling an estimated $1.9K and leaving 48 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Essential Partners first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.76K in Q4 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Essential Partners held 48 shares of UroGen Pharma worth $1.77K as of Q2 2026.
  • Essential Partners sold 70 UroGen Pharma shares in Q2 2026, an estimated $1.9K.
  • UroGen Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2027 holding.
  • Essential Partners first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's UroGen Pharma position peaked at $2.76K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.